Atogepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Preventive treatment of migraine

Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under clini- cal investigation for preventive treatment of migraine. Its inhibitory activity on vasodilatory response has been well demonstrated in vitro. Although pharmacokinetic and metabolism data are still not available, a recently completed phase II clinical trial reported a satisfactory safety and tolerability profile over a 12-week treatment period with doses ranging from 10 to 120 mg daily, with no occurring drug-related serious adverse events. Several other phase III open-label and placebo-controlled clinical trials are ongoing to evaluate atogepant safety in long- term administration. Atogepant showed a significant and clinically relevant efficacy in the decrease in migraine days compared to placebo. Drug–drug interactions po- tentially affecting atogepant pharmacokinetics should be assessed in future clinical trials.